PFE vs VKTX
PFE: Global biopharmaceutical company discovering, developing, and manufacturing prescription medicines and vaccines across oncology, immunology, cardiovascular, and infectious disease. VKTX: A clinical-stage biopharmaceutical company developing next-generation dual GLP-1/GIP receptor agonists for the treatment of obesity and metabolic disorders.
Side-by-side fundamentals
| Metric | PFE | VKTX | Edge |
|---|---|---|---|
| Price as of 2026-07-27 close | $24.67 | $31.74 | |
| Market cap as of 2026-08-03 | $140.6B | $3.7B | |
| P/E as of 2026-08-03 | 19.03 | n/a | |
| PEG as of 2026-08-03 | -2.72 | -0.03 | PFE lower |
| Net margin as of 2026-08-03 | +11.8% | n/a | |
| Gross margin as of 2026-08-03 | +74.8% | n/a | |
| Operating margin as of 2026-08-03 | +15.4% | n/a | |
| ROE as of 2026-08-03 | +8.4% | -71.3% | PFE higher |
| ROA as of 2026-08-03 | +3.6% | -65.3% | PFE higher |
| Debt / equity as of 2026-08-03 | 0.72 | 0.00 | VKTX lower |
| Revenue growth (YoY) as of 2026-08-03 | +1.4% | n/a | |
| Revenue CAGR (3y) SEC XBRL | -14.8% | n/a | |
| Dividend yield as of 2026-08-03 | +6.9% | n/a | |
| Dividend streak (yrs) SEC XBRL | 5 | n/a | |
| Beta as of 2026-08-03 | 0.28 | 1.53 | |
| 1-year return as of 2026-07-27 close | -0.5% | -2.5% | PFE higher |
Fundamentals: market data, as of 2026-08-03. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-27.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.